Global GLP-1 Agonists for Obesity Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
GLP-1 (glucagon-like peptide-1) agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with Type 2 diabetes. Some GLP-1 agonists have been approved to help treat obesity. GLP-1 agonists have been shown to be effective in promoting weight loss in preclinical and clinical studies.
The global GLP-1 Agonists for Obesity market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “GLP-1 Agonists for Obesity Industry Forecast” looks at past sales and reviews total world GLP-1 Agonists for Obesity sales in 2023, providing a comprehensive analysis by region and market sector of projected GLP-1 Agonists for Obesity sales for 2024 through 2030. With GLP-1 Agonists for Obesity sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world GLP-1 Agonists for Obesity industry.
This Insight Report provides a comprehensive analysis of the global GLP-1 Agonists for Obesity landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on GLP-1 Agonists for Obesity portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global GLP-1 Agonists for Obesity market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for GLP-1 Agonists for Obesity and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global GLP-1 Agonists for Obesity.
United States market for GLP-1 Agonists for Obesity is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for GLP-1 Agonists for Obesity is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for GLP-1 Agonists for Obesity is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key GLP-1 Agonists for Obesity players cover Novo Nordisk, Eli Lilly, Huadong Medicine, Shanghai Benemae Pharmaceutical Corporation, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of GLP-1 Agonists for Obesity market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global GLP-1 Agonists for Obesity market?
What factors are driving GLP-1 Agonists for Obesity market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do GLP-1 Agonists for Obesity market opportunities vary by end market size?
How does GLP-1 Agonists for Obesity break out by Type, by Application?
GLP-1 (glucagon-like peptide-1) agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with Type 2 diabetes. Some GLP-1 agonists have been approved to help treat obesity. GLP-1 agonists have been shown to be effective in promoting weight loss in preclinical and clinical studies.
The global GLP-1 Agonists for Obesity market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “GLP-1 Agonists for Obesity Industry Forecast” looks at past sales and reviews total world GLP-1 Agonists for Obesity sales in 2023, providing a comprehensive analysis by region and market sector of projected GLP-1 Agonists for Obesity sales for 2024 through 2030. With GLP-1 Agonists for Obesity sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world GLP-1 Agonists for Obesity industry.
This Insight Report provides a comprehensive analysis of the global GLP-1 Agonists for Obesity landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on GLP-1 Agonists for Obesity portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global GLP-1 Agonists for Obesity market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for GLP-1 Agonists for Obesity and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global GLP-1 Agonists for Obesity.
United States market for GLP-1 Agonists for Obesity is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for GLP-1 Agonists for Obesity is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for GLP-1 Agonists for Obesity is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key GLP-1 Agonists for Obesity players cover Novo Nordisk, Eli Lilly, Huadong Medicine, Shanghai Benemae Pharmaceutical Corporation, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of GLP-1 Agonists for Obesity market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Semaglutide
- Tirzepatide
- Liraglutide
- Benaglutide
- Hospital Pharmaty
- Retail Pharmaty
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Novo Nordisk
- Eli Lilly
- Huadong Medicine
- Shanghai Benemae Pharmaceutical Corporation
What is the 10-year outlook for the global GLP-1 Agonists for Obesity market?
What factors are driving GLP-1 Agonists for Obesity market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do GLP-1 Agonists for Obesity market opportunities vary by end market size?
How does GLP-1 Agonists for Obesity break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global GLP-1 Agonists for Obesity Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for GLP-1 Agonists for Obesity by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for GLP-1 Agonists for Obesity by Country/Region, 2019, 2023 & 2030
2.2 GLP-1 Agonists for Obesity Segment by Type
2.2.1 Semaglutide
2.2.2 Tirzepatide
2.2.3 Liraglutide
2.2.4 Benaglutide
2.3 GLP-1 Agonists for Obesity Sales by Type
2.3.1 Global GLP-1 Agonists for Obesity Sales Market Share by Type (2019-2024)
2.3.2 Global GLP-1 Agonists for Obesity Revenue and Market Share by Type (2019-2024)
2.3.3 Global GLP-1 Agonists for Obesity Sale Price by Type (2019-2024)
2.4 GLP-1 Agonists for Obesity Segment by Application
2.4.1 Hospital Pharmaty
2.4.2 Retail Pharmaty
2.4.3 Others
2.5 GLP-1 Agonists for Obesity Sales by Application
2.5.1 Global GLP-1 Agonists for Obesity Sale Market Share by Application (2019-2024)
2.5.2 Global GLP-1 Agonists for Obesity Revenue and Market Share by Application (2019-2024)
2.5.3 Global GLP-1 Agonists for Obesity Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global GLP-1 Agonists for Obesity Breakdown Data by Company
3.1.1 Global GLP-1 Agonists for Obesity Annual Sales by Company (2019-2024)
3.1.2 Global GLP-1 Agonists for Obesity Sales Market Share by Company (2019-2024)
3.2 Global GLP-1 Agonists for Obesity Annual Revenue by Company (2019-2024)
3.2.1 Global GLP-1 Agonists for Obesity Revenue by Company (2019-2024)
3.2.2 Global GLP-1 Agonists for Obesity Revenue Market Share by Company (2019-2024)
3.3 Global GLP-1 Agonists for Obesity Sale Price by Company
3.4 Key Manufacturers GLP-1 Agonists for Obesity Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers GLP-1 Agonists for Obesity Product Location Distribution
3.4.2 Players GLP-1 Agonists for Obesity Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR GLP-1 AGONISTS FOR OBESITY BY GEOGRAPHIC REGION
4.1 World Historic GLP-1 Agonists for Obesity Market Size by Geographic Region (2019-2024)
4.1.1 Global GLP-1 Agonists for Obesity Annual Sales by Geographic Region (2019-2024)
4.1.2 Global GLP-1 Agonists for Obesity Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic GLP-1 Agonists for Obesity Market Size by Country/Region (2019-2024)
4.2.1 Global GLP-1 Agonists for Obesity Annual Sales by Country/Region (2019-2024)
4.2.2 Global GLP-1 Agonists for Obesity Annual Revenue by Country/Region (2019-2024)
4.3 Americas GLP-1 Agonists for Obesity Sales Growth
4.4 APAC GLP-1 Agonists for Obesity Sales Growth
4.5 Europe GLP-1 Agonists for Obesity Sales Growth
4.6 Middle East & Africa GLP-1 Agonists for Obesity Sales Growth
5 AMERICAS
5.1 Americas GLP-1 Agonists for Obesity Sales by Country
5.1.1 Americas GLP-1 Agonists for Obesity Sales by Country (2019-2024)
5.1.2 Americas GLP-1 Agonists for Obesity Revenue by Country (2019-2024)
5.2 Americas GLP-1 Agonists for Obesity Sales by Type (2019-2024)
5.3 Americas GLP-1 Agonists for Obesity Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC GLP-1 Agonists for Obesity Sales by Region
6.1.1 APAC GLP-1 Agonists for Obesity Sales by Region (2019-2024)
6.1.2 APAC GLP-1 Agonists for Obesity Revenue by Region (2019-2024)
6.2 APAC GLP-1 Agonists for Obesity Sales by Type (2019-2024)
6.3 APAC GLP-1 Agonists for Obesity Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe GLP-1 Agonists for Obesity by Country
7.1.1 Europe GLP-1 Agonists for Obesity Sales by Country (2019-2024)
7.1.2 Europe GLP-1 Agonists for Obesity Revenue by Country (2019-2024)
7.2 Europe GLP-1 Agonists for Obesity Sales by Type (2019-2024)
7.3 Europe GLP-1 Agonists for Obesity Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa GLP-1 Agonists for Obesity by Country
8.1.1 Middle East & Africa GLP-1 Agonists for Obesity Sales by Country (2019-2024)
8.1.2 Middle East & Africa GLP-1 Agonists for Obesity Revenue by Country (2019-2024)
8.2 Middle East & Africa GLP-1 Agonists for Obesity Sales by Type (2019-2024)
8.3 Middle East & Africa GLP-1 Agonists for Obesity Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of GLP-1 Agonists for Obesity
10.3 Manufacturing Process Analysis of GLP-1 Agonists for Obesity
10.4 Industry Chain Structure of GLP-1 Agonists for Obesity
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 GLP-1 Agonists for Obesity Distributors
11.3 GLP-1 Agonists for Obesity Customer
12 WORLD FORECAST REVIEW FOR GLP-1 AGONISTS FOR OBESITY BY GEOGRAPHIC REGION
12.1 Global GLP-1 Agonists for Obesity Market Size Forecast by Region
12.1.1 Global GLP-1 Agonists for Obesity Forecast by Region (2025-2030)
12.1.2 Global GLP-1 Agonists for Obesity Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global GLP-1 Agonists for Obesity Forecast by Type (2025-2030)
12.7 Global GLP-1 Agonists for Obesity Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Novo Nordisk
13.1.1 Novo Nordisk Company Information
13.1.2 Novo Nordisk GLP-1 Agonists for Obesity Product Portfolios and Specifications
13.1.3 Novo Nordisk GLP-1 Agonists for Obesity Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Novo Nordisk Main Business Overview
13.1.5 Novo Nordisk Latest Developments
13.2 Eli Lilly
13.2.1 Eli Lilly Company Information
13.2.2 Eli Lilly GLP-1 Agonists for Obesity Product Portfolios and Specifications
13.2.3 Eli Lilly GLP-1 Agonists for Obesity Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Eli Lilly Main Business Overview
13.2.5 Eli Lilly Latest Developments
13.3 Huadong Medicine
13.3.1 Huadong Medicine Company Information
13.3.2 Huadong Medicine GLP-1 Agonists for Obesity Product Portfolios and Specifications
13.3.3 Huadong Medicine GLP-1 Agonists for Obesity Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Huadong Medicine Main Business Overview
13.3.5 Huadong Medicine Latest Developments
13.4 Shanghai Benemae Pharmaceutical Corporation
13.4.1 Shanghai Benemae Pharmaceutical Corporation Company Information
13.4.2 Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Product Portfolios and Specifications
13.4.3 Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Shanghai Benemae Pharmaceutical Corporation Main Business Overview
13.4.5 Shanghai Benemae Pharmaceutical Corporation Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global GLP-1 Agonists for Obesity Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for GLP-1 Agonists for Obesity by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for GLP-1 Agonists for Obesity by Country/Region, 2019, 2023 & 2030
2.2 GLP-1 Agonists for Obesity Segment by Type
2.2.1 Semaglutide
2.2.2 Tirzepatide
2.2.3 Liraglutide
2.2.4 Benaglutide
2.3 GLP-1 Agonists for Obesity Sales by Type
2.3.1 Global GLP-1 Agonists for Obesity Sales Market Share by Type (2019-2024)
2.3.2 Global GLP-1 Agonists for Obesity Revenue and Market Share by Type (2019-2024)
2.3.3 Global GLP-1 Agonists for Obesity Sale Price by Type (2019-2024)
2.4 GLP-1 Agonists for Obesity Segment by Application
2.4.1 Hospital Pharmaty
2.4.2 Retail Pharmaty
2.4.3 Others
2.5 GLP-1 Agonists for Obesity Sales by Application
2.5.1 Global GLP-1 Agonists for Obesity Sale Market Share by Application (2019-2024)
2.5.2 Global GLP-1 Agonists for Obesity Revenue and Market Share by Application (2019-2024)
2.5.3 Global GLP-1 Agonists for Obesity Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global GLP-1 Agonists for Obesity Breakdown Data by Company
3.1.1 Global GLP-1 Agonists for Obesity Annual Sales by Company (2019-2024)
3.1.2 Global GLP-1 Agonists for Obesity Sales Market Share by Company (2019-2024)
3.2 Global GLP-1 Agonists for Obesity Annual Revenue by Company (2019-2024)
3.2.1 Global GLP-1 Agonists for Obesity Revenue by Company (2019-2024)
3.2.2 Global GLP-1 Agonists for Obesity Revenue Market Share by Company (2019-2024)
3.3 Global GLP-1 Agonists for Obesity Sale Price by Company
3.4 Key Manufacturers GLP-1 Agonists for Obesity Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers GLP-1 Agonists for Obesity Product Location Distribution
3.4.2 Players GLP-1 Agonists for Obesity Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR GLP-1 AGONISTS FOR OBESITY BY GEOGRAPHIC REGION
4.1 World Historic GLP-1 Agonists for Obesity Market Size by Geographic Region (2019-2024)
4.1.1 Global GLP-1 Agonists for Obesity Annual Sales by Geographic Region (2019-2024)
4.1.2 Global GLP-1 Agonists for Obesity Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic GLP-1 Agonists for Obesity Market Size by Country/Region (2019-2024)
4.2.1 Global GLP-1 Agonists for Obesity Annual Sales by Country/Region (2019-2024)
4.2.2 Global GLP-1 Agonists for Obesity Annual Revenue by Country/Region (2019-2024)
4.3 Americas GLP-1 Agonists for Obesity Sales Growth
4.4 APAC GLP-1 Agonists for Obesity Sales Growth
4.5 Europe GLP-1 Agonists for Obesity Sales Growth
4.6 Middle East & Africa GLP-1 Agonists for Obesity Sales Growth
5 AMERICAS
5.1 Americas GLP-1 Agonists for Obesity Sales by Country
5.1.1 Americas GLP-1 Agonists for Obesity Sales by Country (2019-2024)
5.1.2 Americas GLP-1 Agonists for Obesity Revenue by Country (2019-2024)
5.2 Americas GLP-1 Agonists for Obesity Sales by Type (2019-2024)
5.3 Americas GLP-1 Agonists for Obesity Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC GLP-1 Agonists for Obesity Sales by Region
6.1.1 APAC GLP-1 Agonists for Obesity Sales by Region (2019-2024)
6.1.2 APAC GLP-1 Agonists for Obesity Revenue by Region (2019-2024)
6.2 APAC GLP-1 Agonists for Obesity Sales by Type (2019-2024)
6.3 APAC GLP-1 Agonists for Obesity Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe GLP-1 Agonists for Obesity by Country
7.1.1 Europe GLP-1 Agonists for Obesity Sales by Country (2019-2024)
7.1.2 Europe GLP-1 Agonists for Obesity Revenue by Country (2019-2024)
7.2 Europe GLP-1 Agonists for Obesity Sales by Type (2019-2024)
7.3 Europe GLP-1 Agonists for Obesity Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa GLP-1 Agonists for Obesity by Country
8.1.1 Middle East & Africa GLP-1 Agonists for Obesity Sales by Country (2019-2024)
8.1.2 Middle East & Africa GLP-1 Agonists for Obesity Revenue by Country (2019-2024)
8.2 Middle East & Africa GLP-1 Agonists for Obesity Sales by Type (2019-2024)
8.3 Middle East & Africa GLP-1 Agonists for Obesity Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of GLP-1 Agonists for Obesity
10.3 Manufacturing Process Analysis of GLP-1 Agonists for Obesity
10.4 Industry Chain Structure of GLP-1 Agonists for Obesity
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 GLP-1 Agonists for Obesity Distributors
11.3 GLP-1 Agonists for Obesity Customer
12 WORLD FORECAST REVIEW FOR GLP-1 AGONISTS FOR OBESITY BY GEOGRAPHIC REGION
12.1 Global GLP-1 Agonists for Obesity Market Size Forecast by Region
12.1.1 Global GLP-1 Agonists for Obesity Forecast by Region (2025-2030)
12.1.2 Global GLP-1 Agonists for Obesity Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global GLP-1 Agonists for Obesity Forecast by Type (2025-2030)
12.7 Global GLP-1 Agonists for Obesity Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Novo Nordisk
13.1.1 Novo Nordisk Company Information
13.1.2 Novo Nordisk GLP-1 Agonists for Obesity Product Portfolios and Specifications
13.1.3 Novo Nordisk GLP-1 Agonists for Obesity Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Novo Nordisk Main Business Overview
13.1.5 Novo Nordisk Latest Developments
13.2 Eli Lilly
13.2.1 Eli Lilly Company Information
13.2.2 Eli Lilly GLP-1 Agonists for Obesity Product Portfolios and Specifications
13.2.3 Eli Lilly GLP-1 Agonists for Obesity Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Eli Lilly Main Business Overview
13.2.5 Eli Lilly Latest Developments
13.3 Huadong Medicine
13.3.1 Huadong Medicine Company Information
13.3.2 Huadong Medicine GLP-1 Agonists for Obesity Product Portfolios and Specifications
13.3.3 Huadong Medicine GLP-1 Agonists for Obesity Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Huadong Medicine Main Business Overview
13.3.5 Huadong Medicine Latest Developments
13.4 Shanghai Benemae Pharmaceutical Corporation
13.4.1 Shanghai Benemae Pharmaceutical Corporation Company Information
13.4.2 Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Product Portfolios and Specifications
13.4.3 Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Shanghai Benemae Pharmaceutical Corporation Main Business Overview
13.4.5 Shanghai Benemae Pharmaceutical Corporation Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. GLP-1 Agonists for Obesity Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. GLP-1 Agonists for Obesity Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Semaglutide
Table 4. Major Players of Tirzepatide
Table 5. Major Players of Liraglutide
Table 6. Major Players of Benaglutide
Table 7. Global GLP-1 Agonists for Obesity Sales by Type (2019-2024) & (K Dose)
Table 8. Global GLP-1 Agonists for Obesity Sales Market Share by Type (2019-2024)
Table 9. Global GLP-1 Agonists for Obesity Revenue by Type (2019-2024) & ($ million)
Table 10. Global GLP-1 Agonists for Obesity Revenue Market Share by Type (2019-2024)
Table 11. Global GLP-1 Agonists for Obesity Sale Price by Type (2019-2024) & (US$/Dose)
Table 12. Global GLP-1 Agonists for Obesity Sale by Application (2019-2024) & (K Dose)
Table 13. Global GLP-1 Agonists for Obesity Sale Market Share by Application (2019-2024)
Table 14. Global GLP-1 Agonists for Obesity Revenue by Application (2019-2024) & ($ million)
Table 15. Global GLP-1 Agonists for Obesity Revenue Market Share by Application (2019-2024)
Table 16. Global GLP-1 Agonists for Obesity Sale Price by Application (2019-2024) & (US$/Dose)
Table 17. Global GLP-1 Agonists for Obesity Sales by Company (2019-2024) & (K Dose)
Table 18. Global GLP-1 Agonists for Obesity Sales Market Share by Company (2019-2024)
Table 19. Global GLP-1 Agonists for Obesity Revenue by Company (2019-2024) & ($ millions)
Table 20. Global GLP-1 Agonists for Obesity Revenue Market Share by Company (2019-2024)
Table 21. Global GLP-1 Agonists for Obesity Sale Price by Company (2019-2024) & (US$/Dose)
Table 22. Key Manufacturers GLP-1 Agonists for Obesity Producing Area Distribution and Sales Area
Table 23. Players GLP-1 Agonists for Obesity Products Offered
Table 24. GLP-1 Agonists for Obesity Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global GLP-1 Agonists for Obesity Sales by Geographic Region (2019-2024) & (K Dose)
Table 28. Global GLP-1 Agonists for Obesity Sales Market Share Geographic Region (2019-2024)
Table 29. Global GLP-1 Agonists for Obesity Revenue by Geographic Region (2019-2024) & ($ millions)
Table 30. Global GLP-1 Agonists for Obesity Revenue Market Share by Geographic Region (2019-2024)
Table 31. Global GLP-1 Agonists for Obesity Sales by Country/Region (2019-2024) & (K Dose)
Table 32. Global GLP-1 Agonists for Obesity Sales Market Share by Country/Region (2019-2024)
Table 33. Global GLP-1 Agonists for Obesity Revenue by Country/Region (2019-2024) & ($ millions)
Table 34. Global GLP-1 Agonists for Obesity Revenue Market Share by Country/Region (2019-2024)
Table 35. Americas GLP-1 Agonists for Obesity Sales by Country (2019-2024) & (K Dose)
Table 36. Americas GLP-1 Agonists for Obesity Sales Market Share by Country (2019-2024)
Table 37. Americas GLP-1 Agonists for Obesity Revenue by Country (2019-2024) & ($ millions)
Table 38. Americas GLP-1 Agonists for Obesity Sales by Type (2019-2024) & (K Dose)
Table 39. Americas GLP-1 Agonists for Obesity Sales by Application (2019-2024) & (K Dose)
Table 40. APAC GLP-1 Agonists for Obesity Sales by Region (2019-2024) & (K Dose)
Table 41. APAC GLP-1 Agonists for Obesity Sales Market Share by Region (2019-2024)
Table 42. APAC GLP-1 Agonists for Obesity Revenue by Region (2019-2024) & ($ millions)
Table 43. APAC GLP-1 Agonists for Obesity Sales by Type (2019-2024) & (K Dose)
Table 44. APAC GLP-1 Agonists for Obesity Sales by Application (2019-2024) & (K Dose)
Table 45. Europe GLP-1 Agonists for Obesity Sales by Country (2019-2024) & (K Dose)
Table 46. Europe GLP-1 Agonists for Obesity Revenue by Country (2019-2024) & ($ millions)
Table 47. Europe GLP-1 Agonists for Obesity Sales by Type (2019-2024) & (K Dose)
Table 48. Europe GLP-1 Agonists for Obesity Sales by Application (2019-2024) & (K Dose)
Table 49. Middle East & Africa GLP-1 Agonists for Obesity Sales by Country (2019-2024) & (K Dose)
Table 50. Middle East & Africa GLP-1 Agonists for Obesity Revenue Market Share by Country (2019-2024)
Table 51. Middle East & Africa GLP-1 Agonists for Obesity Sales by Type (2019-2024) & (K Dose)
Table 52. Middle East & Africa GLP-1 Agonists for Obesity Sales by Application (2019-2024) & (K Dose)
Table 53. Key Market Drivers & Growth Opportunities of GLP-1 Agonists for Obesity
Table 54. Key Market Challenges & Risks of GLP-1 Agonists for Obesity
Table 55. Key Industry Trends of GLP-1 Agonists for Obesity
Table 56. GLP-1 Agonists for Obesity Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. GLP-1 Agonists for Obesity Distributors List
Table 59. GLP-1 Agonists for Obesity Customer List
Table 60. Global GLP-1 Agonists for Obesity Sales Forecast by Region (2025-2030) & (K Dose)
Table 61. Global GLP-1 Agonists for Obesity Revenue Forecast by Region (2025-2030) & ($ millions)
Table 62. Americas GLP-1 Agonists for Obesity Sales Forecast by Country (2025-2030) & (K Dose)
Table 63. Americas GLP-1 Agonists for Obesity Annual Revenue Forecast by Country (2025-2030) & ($ millions)
Table 64. APAC GLP-1 Agonists for Obesity Sales Forecast by Region (2025-2030) & (K Dose)
Table 65. APAC GLP-1 Agonists for Obesity Annual Revenue Forecast by Region (2025-2030) & ($ millions)
Table 66. Europe GLP-1 Agonists for Obesity Sales Forecast by Country (2025-2030) & (K Dose)
Table 67. Europe GLP-1 Agonists for Obesity Revenue Forecast by Country (2025-2030) & ($ millions)
Table 68. Middle East & Africa GLP-1 Agonists for Obesity Sales Forecast by Country (2025-2030) & (K Dose)
Table 69. Middle East & Africa GLP-1 Agonists for Obesity Revenue Forecast by Country (2025-2030) & ($ millions)
Table 70. Global GLP-1 Agonists for Obesity Sales Forecast by Type (2025-2030) & (K Dose)
Table 71. Global GLP-1 Agonists for Obesity Revenue Forecast by Type (2025-2030) & ($ millions)
Table 72. Global GLP-1 Agonists for Obesity Sales Forecast by Application (2025-2030) & (K Dose)
Table 73. Global GLP-1 Agonists for Obesity Revenue Forecast by Application (2025-2030) & ($ millions)
Table 74. Novo Nordisk Basic Information, GLP-1 Agonists for Obesity Manufacturing Base, Sales Area and Its Competitors
Table 75. Novo Nordisk GLP-1 Agonists for Obesity Product Portfolios and Specifications
Table 76. Novo Nordisk GLP-1 Agonists for Obesity Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 77. Novo Nordisk Main Business
Table 78. Novo Nordisk Latest Developments
Table 79. Eli Lilly Basic Information, GLP-1 Agonists for Obesity Manufacturing Base, Sales Area and Its Competitors
Table 80. Eli Lilly GLP-1 Agonists for Obesity Product Portfolios and Specifications
Table 81. Eli Lilly GLP-1 Agonists for Obesity Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 82. Eli Lilly Main Business
Table 83. Eli Lilly Latest Developments
Table 84. Huadong Medicine Basic Information, GLP-1 Agonists for Obesity Manufacturing Base, Sales Area and Its Competitors
Table 85. Huadong Medicine GLP-1 Agonists for Obesity Product Portfolios and Specifications
Table 86. Huadong Medicine GLP-1 Agonists for Obesity Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 87. Huadong Medicine Main Business
Table 88. Huadong Medicine Latest Developments
Table 89. Shanghai Benemae Pharmaceutical Corporation Basic Information, GLP-1 Agonists for Obesity Manufacturing Base, Sales Area and Its Competitors
Table 90. Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Product Portfolios and Specifications
Table 91. Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 92. Shanghai Benemae Pharmaceutical Corporation Main Business
Table 93. Shanghai Benemae Pharmaceutical Corporation Latest Developments
Table 1. GLP-1 Agonists for Obesity Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. GLP-1 Agonists for Obesity Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Semaglutide
Table 4. Major Players of Tirzepatide
Table 5. Major Players of Liraglutide
Table 6. Major Players of Benaglutide
Table 7. Global GLP-1 Agonists for Obesity Sales by Type (2019-2024) & (K Dose)
Table 8. Global GLP-1 Agonists for Obesity Sales Market Share by Type (2019-2024)
Table 9. Global GLP-1 Agonists for Obesity Revenue by Type (2019-2024) & ($ million)
Table 10. Global GLP-1 Agonists for Obesity Revenue Market Share by Type (2019-2024)
Table 11. Global GLP-1 Agonists for Obesity Sale Price by Type (2019-2024) & (US$/Dose)
Table 12. Global GLP-1 Agonists for Obesity Sale by Application (2019-2024) & (K Dose)
Table 13. Global GLP-1 Agonists for Obesity Sale Market Share by Application (2019-2024)
Table 14. Global GLP-1 Agonists for Obesity Revenue by Application (2019-2024) & ($ million)
Table 15. Global GLP-1 Agonists for Obesity Revenue Market Share by Application (2019-2024)
Table 16. Global GLP-1 Agonists for Obesity Sale Price by Application (2019-2024) & (US$/Dose)
Table 17. Global GLP-1 Agonists for Obesity Sales by Company (2019-2024) & (K Dose)
Table 18. Global GLP-1 Agonists for Obesity Sales Market Share by Company (2019-2024)
Table 19. Global GLP-1 Agonists for Obesity Revenue by Company (2019-2024) & ($ millions)
Table 20. Global GLP-1 Agonists for Obesity Revenue Market Share by Company (2019-2024)
Table 21. Global GLP-1 Agonists for Obesity Sale Price by Company (2019-2024) & (US$/Dose)
Table 22. Key Manufacturers GLP-1 Agonists for Obesity Producing Area Distribution and Sales Area
Table 23. Players GLP-1 Agonists for Obesity Products Offered
Table 24. GLP-1 Agonists for Obesity Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global GLP-1 Agonists for Obesity Sales by Geographic Region (2019-2024) & (K Dose)
Table 28. Global GLP-1 Agonists for Obesity Sales Market Share Geographic Region (2019-2024)
Table 29. Global GLP-1 Agonists for Obesity Revenue by Geographic Region (2019-2024) & ($ millions)
Table 30. Global GLP-1 Agonists for Obesity Revenue Market Share by Geographic Region (2019-2024)
Table 31. Global GLP-1 Agonists for Obesity Sales by Country/Region (2019-2024) & (K Dose)
Table 32. Global GLP-1 Agonists for Obesity Sales Market Share by Country/Region (2019-2024)
Table 33. Global GLP-1 Agonists for Obesity Revenue by Country/Region (2019-2024) & ($ millions)
Table 34. Global GLP-1 Agonists for Obesity Revenue Market Share by Country/Region (2019-2024)
Table 35. Americas GLP-1 Agonists for Obesity Sales by Country (2019-2024) & (K Dose)
Table 36. Americas GLP-1 Agonists for Obesity Sales Market Share by Country (2019-2024)
Table 37. Americas GLP-1 Agonists for Obesity Revenue by Country (2019-2024) & ($ millions)
Table 38. Americas GLP-1 Agonists for Obesity Sales by Type (2019-2024) & (K Dose)
Table 39. Americas GLP-1 Agonists for Obesity Sales by Application (2019-2024) & (K Dose)
Table 40. APAC GLP-1 Agonists for Obesity Sales by Region (2019-2024) & (K Dose)
Table 41. APAC GLP-1 Agonists for Obesity Sales Market Share by Region (2019-2024)
Table 42. APAC GLP-1 Agonists for Obesity Revenue by Region (2019-2024) & ($ millions)
Table 43. APAC GLP-1 Agonists for Obesity Sales by Type (2019-2024) & (K Dose)
Table 44. APAC GLP-1 Agonists for Obesity Sales by Application (2019-2024) & (K Dose)
Table 45. Europe GLP-1 Agonists for Obesity Sales by Country (2019-2024) & (K Dose)
Table 46. Europe GLP-1 Agonists for Obesity Revenue by Country (2019-2024) & ($ millions)
Table 47. Europe GLP-1 Agonists for Obesity Sales by Type (2019-2024) & (K Dose)
Table 48. Europe GLP-1 Agonists for Obesity Sales by Application (2019-2024) & (K Dose)
Table 49. Middle East & Africa GLP-1 Agonists for Obesity Sales by Country (2019-2024) & (K Dose)
Table 50. Middle East & Africa GLP-1 Agonists for Obesity Revenue Market Share by Country (2019-2024)
Table 51. Middle East & Africa GLP-1 Agonists for Obesity Sales by Type (2019-2024) & (K Dose)
Table 52. Middle East & Africa GLP-1 Agonists for Obesity Sales by Application (2019-2024) & (K Dose)
Table 53. Key Market Drivers & Growth Opportunities of GLP-1 Agonists for Obesity
Table 54. Key Market Challenges & Risks of GLP-1 Agonists for Obesity
Table 55. Key Industry Trends of GLP-1 Agonists for Obesity
Table 56. GLP-1 Agonists for Obesity Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. GLP-1 Agonists for Obesity Distributors List
Table 59. GLP-1 Agonists for Obesity Customer List
Table 60. Global GLP-1 Agonists for Obesity Sales Forecast by Region (2025-2030) & (K Dose)
Table 61. Global GLP-1 Agonists for Obesity Revenue Forecast by Region (2025-2030) & ($ millions)
Table 62. Americas GLP-1 Agonists for Obesity Sales Forecast by Country (2025-2030) & (K Dose)
Table 63. Americas GLP-1 Agonists for Obesity Annual Revenue Forecast by Country (2025-2030) & ($ millions)
Table 64. APAC GLP-1 Agonists for Obesity Sales Forecast by Region (2025-2030) & (K Dose)
Table 65. APAC GLP-1 Agonists for Obesity Annual Revenue Forecast by Region (2025-2030) & ($ millions)
Table 66. Europe GLP-1 Agonists for Obesity Sales Forecast by Country (2025-2030) & (K Dose)
Table 67. Europe GLP-1 Agonists for Obesity Revenue Forecast by Country (2025-2030) & ($ millions)
Table 68. Middle East & Africa GLP-1 Agonists for Obesity Sales Forecast by Country (2025-2030) & (K Dose)
Table 69. Middle East & Africa GLP-1 Agonists for Obesity Revenue Forecast by Country (2025-2030) & ($ millions)
Table 70. Global GLP-1 Agonists for Obesity Sales Forecast by Type (2025-2030) & (K Dose)
Table 71. Global GLP-1 Agonists for Obesity Revenue Forecast by Type (2025-2030) & ($ millions)
Table 72. Global GLP-1 Agonists for Obesity Sales Forecast by Application (2025-2030) & (K Dose)
Table 73. Global GLP-1 Agonists for Obesity Revenue Forecast by Application (2025-2030) & ($ millions)
Table 74. Novo Nordisk Basic Information, GLP-1 Agonists for Obesity Manufacturing Base, Sales Area and Its Competitors
Table 75. Novo Nordisk GLP-1 Agonists for Obesity Product Portfolios and Specifications
Table 76. Novo Nordisk GLP-1 Agonists for Obesity Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 77. Novo Nordisk Main Business
Table 78. Novo Nordisk Latest Developments
Table 79. Eli Lilly Basic Information, GLP-1 Agonists for Obesity Manufacturing Base, Sales Area and Its Competitors
Table 80. Eli Lilly GLP-1 Agonists for Obesity Product Portfolios and Specifications
Table 81. Eli Lilly GLP-1 Agonists for Obesity Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 82. Eli Lilly Main Business
Table 83. Eli Lilly Latest Developments
Table 84. Huadong Medicine Basic Information, GLP-1 Agonists for Obesity Manufacturing Base, Sales Area and Its Competitors
Table 85. Huadong Medicine GLP-1 Agonists for Obesity Product Portfolios and Specifications
Table 86. Huadong Medicine GLP-1 Agonists for Obesity Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 87. Huadong Medicine Main Business
Table 88. Huadong Medicine Latest Developments
Table 89. Shanghai Benemae Pharmaceutical Corporation Basic Information, GLP-1 Agonists for Obesity Manufacturing Base, Sales Area and Its Competitors
Table 90. Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Product Portfolios and Specifications
Table 91. Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 92. Shanghai Benemae Pharmaceutical Corporation Main Business
Table 93. Shanghai Benemae Pharmaceutical Corporation Latest Developments
LIST OF FIGURES
Figure 1. Picture of GLP-1 Agonists for Obesity
Figure 2. GLP-1 Agonists for Obesity Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global GLP-1 Agonists for Obesity Sales Growth Rate 2019-2030 (K Dose)
Figure 7. Global GLP-1 Agonists for Obesity Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. GLP-1 Agonists for Obesity Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. GLP-1 Agonists for Obesity Sales Market Share by Country/Region (2023)
Figure 10. GLP-1 Agonists for Obesity Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of Semaglutide
Figure 12. Product Picture of Tirzepatide
Figure 13. Product Picture of Liraglutide
Figure 14. Product Picture of Benaglutide
Figure 15. Global GLP-1 Agonists for Obesity Sales Market Share by Type in 2023
Figure 16. Global GLP-1 Agonists for Obesity Revenue Market Share by Type (2019-2024)
Figure 17. GLP-1 Agonists for Obesity Consumed in Hospital Pharmaty
Figure 18. Global GLP-1 Agonists for Obesity Market: Hospital Pharmaty (2019-2024) & (K Dose)
Figure 19. GLP-1 Agonists for Obesity Consumed in Retail Pharmaty
Figure 20. Global GLP-1 Agonists for Obesity Market: Retail Pharmaty (2019-2024) & (K Dose)
Figure 21. GLP-1 Agonists for Obesity Consumed in Others
Figure 22. Global GLP-1 Agonists for Obesity Market: Others (2019-2024) & (K Dose)
Figure 23. Global GLP-1 Agonists for Obesity Sale Market Share by Application (2023)
Figure 24. Global GLP-1 Agonists for Obesity Revenue Market Share by Application in 2023
Figure 25. GLP-1 Agonists for Obesity Sales by Company in 2023 (K Dose)
Figure 26. Global GLP-1 Agonists for Obesity Sales Market Share by Company in 2023
Figure 27. GLP-1 Agonists for Obesity Revenue by Company in 2023 ($ millions)
Figure 28. Global GLP-1 Agonists for Obesity Revenue Market Share by Company in 2023
Figure 29. Global GLP-1 Agonists for Obesity Sales Market Share by Geographic Region (2019-2024)
Figure 30. Global GLP-1 Agonists for Obesity Revenue Market Share by Geographic Region in 2023
Figure 31. Americas GLP-1 Agonists for Obesity Sales 2019-2024 (K Dose)
Figure 32. Americas GLP-1 Agonists for Obesity Revenue 2019-2024 ($ millions)
Figure 33. APAC GLP-1 Agonists for Obesity Sales 2019-2024 (K Dose)
Figure 34. APAC GLP-1 Agonists for Obesity Revenue 2019-2024 ($ millions)
Figure 35. Europe GLP-1 Agonists for Obesity Sales 2019-2024 (K Dose)
Figure 36. Europe GLP-1 Agonists for Obesity Revenue 2019-2024 ($ millions)
Figure 37. Middle East & Africa GLP-1 Agonists for Obesity Sales 2019-2024 (K Dose)
Figure 38. Middle East & Africa GLP-1 Agonists for Obesity Revenue 2019-2024 ($ millions)
Figure 39. Americas GLP-1 Agonists for Obesity Sales Market Share by Country in 2023
Figure 40. Americas GLP-1 Agonists for Obesity Revenue Market Share by Country (2019-2024)
Figure 41. Americas GLP-1 Agonists for Obesity Sales Market Share by Type (2019-2024)
Figure 42. Americas GLP-1 Agonists for Obesity Sales Market Share by Application (2019-2024)
Figure 43. United States GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 44. Canada GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 45. Mexico GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 46. Brazil GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 47. APAC GLP-1 Agonists for Obesity Sales Market Share by Region in 2023
Figure 48. APAC GLP-1 Agonists for Obesity Revenue Market Share by Region (2019-2024)
Figure 49. APAC GLP-1 Agonists for Obesity Sales Market Share by Type (2019-2024)
Figure 50. APAC GLP-1 Agonists for Obesity Sales Market Share by Application (2019-2024)
Figure 51. China GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 52. Japan GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 53. South Korea GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 54. Southeast Asia GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 55. India GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 56. Australia GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 57. China Taiwan GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 58. Europe GLP-1 Agonists for Obesity Sales Market Share by Country in 2023
Figure 59. Europe GLP-1 Agonists for Obesity Revenue Market Share by Country (2019-2024)
Figure 60. Europe GLP-1 Agonists for Obesity Sales Market Share by Type (2019-2024)
Figure 61. Europe GLP-1 Agonists for Obesity Sales Market Share by Application (2019-2024)
Figure 62. Germany GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 63. France GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 64. UK GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 65. Italy GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 66. Russia GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 67. Middle East & Africa GLP-1 Agonists for Obesity Sales Market Share by Country (2019-2024)
Figure 68. Middle East & Africa GLP-1 Agonists for Obesity Sales Market Share by Type (2019-2024)
Figure 69. Middle East & Africa GLP-1 Agonists for Obesity Sales Market Share by Application (2019-2024)
Figure 70. Egypt GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 71. South Africa GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 72. Israel GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 73. Turkey GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 74. GCC Countries GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of GLP-1 Agonists for Obesity in 2023
Figure 76. Manufacturing Process Analysis of GLP-1 Agonists for Obesity
Figure 77. Industry Chain Structure of GLP-1 Agonists for Obesity
Figure 78. Channels of Distribution
Figure 79. Global GLP-1 Agonists for Obesity Sales Market Forecast by Region (2025-2030)
Figure 80. Global GLP-1 Agonists for Obesity Revenue Market Share Forecast by Region (2025-2030)
Figure 81. Global GLP-1 Agonists for Obesity Sales Market Share Forecast by Type (2025-2030)
Figure 82. Global GLP-1 Agonists for Obesity Revenue Market Share Forecast by Type (2025-2030)
Figure 83. Global GLP-1 Agonists for Obesity Sales Market Share Forecast by Application (2025-2030)
Figure 84. Global GLP-1 Agonists for Obesity Revenue Market Share Forecast by Application (2025-2030)
Figure 1. Picture of GLP-1 Agonists for Obesity
Figure 2. GLP-1 Agonists for Obesity Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global GLP-1 Agonists for Obesity Sales Growth Rate 2019-2030 (K Dose)
Figure 7. Global GLP-1 Agonists for Obesity Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. GLP-1 Agonists for Obesity Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. GLP-1 Agonists for Obesity Sales Market Share by Country/Region (2023)
Figure 10. GLP-1 Agonists for Obesity Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of Semaglutide
Figure 12. Product Picture of Tirzepatide
Figure 13. Product Picture of Liraglutide
Figure 14. Product Picture of Benaglutide
Figure 15. Global GLP-1 Agonists for Obesity Sales Market Share by Type in 2023
Figure 16. Global GLP-1 Agonists for Obesity Revenue Market Share by Type (2019-2024)
Figure 17. GLP-1 Agonists for Obesity Consumed in Hospital Pharmaty
Figure 18. Global GLP-1 Agonists for Obesity Market: Hospital Pharmaty (2019-2024) & (K Dose)
Figure 19. GLP-1 Agonists for Obesity Consumed in Retail Pharmaty
Figure 20. Global GLP-1 Agonists for Obesity Market: Retail Pharmaty (2019-2024) & (K Dose)
Figure 21. GLP-1 Agonists for Obesity Consumed in Others
Figure 22. Global GLP-1 Agonists for Obesity Market: Others (2019-2024) & (K Dose)
Figure 23. Global GLP-1 Agonists for Obesity Sale Market Share by Application (2023)
Figure 24. Global GLP-1 Agonists for Obesity Revenue Market Share by Application in 2023
Figure 25. GLP-1 Agonists for Obesity Sales by Company in 2023 (K Dose)
Figure 26. Global GLP-1 Agonists for Obesity Sales Market Share by Company in 2023
Figure 27. GLP-1 Agonists for Obesity Revenue by Company in 2023 ($ millions)
Figure 28. Global GLP-1 Agonists for Obesity Revenue Market Share by Company in 2023
Figure 29. Global GLP-1 Agonists for Obesity Sales Market Share by Geographic Region (2019-2024)
Figure 30. Global GLP-1 Agonists for Obesity Revenue Market Share by Geographic Region in 2023
Figure 31. Americas GLP-1 Agonists for Obesity Sales 2019-2024 (K Dose)
Figure 32. Americas GLP-1 Agonists for Obesity Revenue 2019-2024 ($ millions)
Figure 33. APAC GLP-1 Agonists for Obesity Sales 2019-2024 (K Dose)
Figure 34. APAC GLP-1 Agonists for Obesity Revenue 2019-2024 ($ millions)
Figure 35. Europe GLP-1 Agonists for Obesity Sales 2019-2024 (K Dose)
Figure 36. Europe GLP-1 Agonists for Obesity Revenue 2019-2024 ($ millions)
Figure 37. Middle East & Africa GLP-1 Agonists for Obesity Sales 2019-2024 (K Dose)
Figure 38. Middle East & Africa GLP-1 Agonists for Obesity Revenue 2019-2024 ($ millions)
Figure 39. Americas GLP-1 Agonists for Obesity Sales Market Share by Country in 2023
Figure 40. Americas GLP-1 Agonists for Obesity Revenue Market Share by Country (2019-2024)
Figure 41. Americas GLP-1 Agonists for Obesity Sales Market Share by Type (2019-2024)
Figure 42. Americas GLP-1 Agonists for Obesity Sales Market Share by Application (2019-2024)
Figure 43. United States GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 44. Canada GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 45. Mexico GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 46. Brazil GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 47. APAC GLP-1 Agonists for Obesity Sales Market Share by Region in 2023
Figure 48. APAC GLP-1 Agonists for Obesity Revenue Market Share by Region (2019-2024)
Figure 49. APAC GLP-1 Agonists for Obesity Sales Market Share by Type (2019-2024)
Figure 50. APAC GLP-1 Agonists for Obesity Sales Market Share by Application (2019-2024)
Figure 51. China GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 52. Japan GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 53. South Korea GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 54. Southeast Asia GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 55. India GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 56. Australia GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 57. China Taiwan GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 58. Europe GLP-1 Agonists for Obesity Sales Market Share by Country in 2023
Figure 59. Europe GLP-1 Agonists for Obesity Revenue Market Share by Country (2019-2024)
Figure 60. Europe GLP-1 Agonists for Obesity Sales Market Share by Type (2019-2024)
Figure 61. Europe GLP-1 Agonists for Obesity Sales Market Share by Application (2019-2024)
Figure 62. Germany GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 63. France GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 64. UK GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 65. Italy GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 66. Russia GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 67. Middle East & Africa GLP-1 Agonists for Obesity Sales Market Share by Country (2019-2024)
Figure 68. Middle East & Africa GLP-1 Agonists for Obesity Sales Market Share by Type (2019-2024)
Figure 69. Middle East & Africa GLP-1 Agonists for Obesity Sales Market Share by Application (2019-2024)
Figure 70. Egypt GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 71. South Africa GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 72. Israel GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 73. Turkey GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 74. GCC Countries GLP-1 Agonists for Obesity Revenue Growth 2019-2024 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of GLP-1 Agonists for Obesity in 2023
Figure 76. Manufacturing Process Analysis of GLP-1 Agonists for Obesity
Figure 77. Industry Chain Structure of GLP-1 Agonists for Obesity
Figure 78. Channels of Distribution
Figure 79. Global GLP-1 Agonists for Obesity Sales Market Forecast by Region (2025-2030)
Figure 80. Global GLP-1 Agonists for Obesity Revenue Market Share Forecast by Region (2025-2030)
Figure 81. Global GLP-1 Agonists for Obesity Sales Market Share Forecast by Type (2025-2030)
Figure 82. Global GLP-1 Agonists for Obesity Revenue Market Share Forecast by Type (2025-2030)
Figure 83. Global GLP-1 Agonists for Obesity Sales Market Share Forecast by Application (2025-2030)
Figure 84. Global GLP-1 Agonists for Obesity Revenue Market Share Forecast by Application (2025-2030)
